Brief: Resverlogix And Eversana Announce Partnership To Support The Pending Launch Of The Initial Commercialization Of Apabetalone For Covid-19 In The United States And Canada
03/06/2021 13:07
June 3 (Reuters) - Resverlogix Corp RVX.TO :
* RESVERLOGIX AND EVERSANA ANNOUNCE PARTNERSHIP TO SUPPORT
THE
PENDING LAUNCH OF THE INITIAL COMMERCIALIZATION OF APABETALONE
FOR COVID-19 IN THE UNITED STATES AND CANADA
Source text for Eikon: ID:nGNX3XZq8Z
Further company coverage: RVX.TO
((reuters.briefs@thomsonreuters.com;))
Recent news on Resverlogix
See all newsBrief: Resverlogix Confirms Focus On Treatment Of Post Covid-19 Conditions
Brief: Resverlogix Announces New Research Findings Highlighting Safety Of BD2-Selective BET Inhibitors
Brief: Resverlogix Announces Type C Meeting With FDA For Coral, A Phase 3 High-Risk Covid-19 Outpatient Study
Brief: Resverlogix Expands Phase 2B Clinical Trial For Covid-19 Treatment With First Site In Brazil And Second In Canada
Brief: Resverlogix Announces Commencement Of Patient Enrollment And Dosing In A Phase 2B Trial For COVID-19 Treatment